<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02971800</url>
  </required_header>
  <id_info>
    <org_study_id>FLUO-HTL</org_study_id>
    <nct_id>NCT02971800</nct_id>
  </id_info>
  <brief_title>Evaluation of Sodium Fluorescein Use During Intraoperative Cystoscopy After Total Laparoscopic Hysterectomy</brief_title>
  <official_title>Evaluation of Sodium Fluorescein Use During Intraoperative Cystoscopy After Total Laparoscopic Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to describe the safety and efficacy of intravenous sodium
      fluorescein to visualize ureteral efflux during intraoperative cystoscopy after total
      laparoscopic hysterectomy. Secondary objective is to report on surgeon's satisfaction with
      the overall use of sodium fluorescein.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty patients (n=30) ongoing a total laparoscopic hysterectomy in a tertiary gynecological
      reference center will be included in this prospective descriptive study.Once hysterectomy is
      completed, a 10 % solution of sodium fluorescein at a 0,25 ml dose will be injected before
      performing diagnostic cystoscopy. Time from injection to fluorescent visualization will be
      recorded as well as coloration density. Adverse events are collected in the operating room,
      in the recovery room, before patient's discharge and through a home survey.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of ureteral efflux coloration with sodium fluorescein collected with dedicated questionnaire</measure>
    <time_frame>within 15 minutes after the beginning of cystoscopy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse reaction related to sodium fluorescein injection</measure>
    <time_frame>From sodium fluorescein injection to follow-up 2 months after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgeon satisfaction regarding ureteral efflux visualization by filling out a dedicated questionnaire</measure>
    <time_frame>after cystoscopy (up to 15 min after injection)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Ureteral Injury</condition>
  <arm_group>
    <arm_group_label>sodium fluorescein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once hysterectomy completed, a 10 % solution of sodium fluorescein at a 0,25 ml dose (25 mg) is injected before performing diagnostic cystoscopy for all patient.
Name: Fluorescite Injection 10%, contains sodium fluorescein (equivalent to fluorescein 10% w/v) Dosage : 25 mg Frequency: only once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium fluorescein injection 10%</intervention_name>
    <arm_group_label>sodium fluorescein</arm_group_label>
    <other_name>Fluorescite</other_name>
    <other_name>National Drug Code (NDC) 0065-0092-65</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  total laparoscopic hysterectomy

        Exclusion Criteria:

          -  breastfeeding

          -  renal insufficiency

          -  Medication: Probenecid, digoxin, quinidine

          -  hypersensitivity or intolerance to sodium fluorescein
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Y Laberge, doctorate</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Quebec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Qu√©bec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2016</study_first_submitted>
  <study_first_submitted_qc>November 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2016</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHU de Quebec-Universite Laval</investigator_affiliation>
    <investigator_full_name>Dr Philippe Y Laberge</investigator_full_name>
    <investigator_title>Gynecologist</investigator_title>
  </responsible_party>
  <keyword>sodium fluorescein</keyword>
  <keyword>ureteral efflux</keyword>
  <keyword>laparoscopic hysterectomy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 2, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

